10x Genomics reported stronger-than-expected Q3 2026 financial results, including a revenue beat and narrower net and operating losses. The company subsequently raised its full-year revenue guidance, indicating positive momentum and improved financial health.
10x Genomics announced Q3 2026 results that surpassed analyst expectations for both revenue and earnings, while also showing improved profitability metrics like narrower operating losses and better gross margins. This positive performance led the company to increase its full-year revenue guidance, signaling management's confidence in continued growth. This is a significant positive catalyst for TXG stock in the short term, as it suggests a stronger financial trajectory than previously anticipated. For traders, this indicates an opportunity for upward price movement, although long-term implications will depend on sustained execution and market demand for their genomics products.